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The antibody (Ab) l response of A/J mice to the p-azobenzenearsonate (ABA) 
hapten includes a  substantial cross-reactive idiotypic (CRI or IdX) component 
(1).  Serological  (2)  and  amino  acid  sequence  (3-5)  studies  on  ABA-specific 
monoclonal Abs (mAb or HP) produced by hybridomas (derived using A/J ABA- 
hyperimmune splenocytes) have indicated that all the HP examined are unique. 
However, CRI  + HP can be shown to share one or more conserved IdX deter- 
minant(s) (6). Despite the microheterogeneity of the family of molecules bearing 
the major CRI, it appears that the heavy chain variable (VH), and probably the 
light chain variable (VL) regions are each encoded by a single germline gene that 
undergoes somatic variation (7,  8).  Recently, Milner and Capra (9) showed that 
the available N-terminal VH sequences could be classed into three distinct VH 
homology families, which might be termed: (a) the CRIA group (prototypes HP: 
R16.7, 93G7 [2], and 36-65 [4]); (b) the CRIc, family (prototypes: HP 92D5 [9] 
and  36-60  [10]);  and,  (c)  the  96B8  family,  which  has  not  previously  been 
serologically detected as a distinct IdX entity in the Ab response. It seems likely 
that these homology families result from the expression of at least three different 
Vu genes present in the strain A germline. 
A comparable complexity was recently demonstrated by Brown et al. (11)  to 
exist at the serological level among induced anti-ABA Abs of A/J mice. Utiliza- 
tion of an anti-Id serum, prepared against HP R 16.7, which had previously been 
shown to bear virtually all of the major CRI determinants found among induced 
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Abs  (2),  permitted  the  further dissection  of the  Id  nature  of the  response.  It 
showed that the following IdX relationships existed among A/J serum anti-ABA 
Abs:  (a) ,--30-50% of these were bound by rabbit (Rbt) anti-CRI sera, so these 
typed as CRI+;  (b)  -~80%  of the CRI ÷ Abs could also be bound by Rbt anti-Id 
R16.7,  and,  thus,  these  were  (by  definition)  CRIA+;  (c)  the  fraction  of CRI +, 
CRIA- Abs was referred to as CRIm +, i.e., positive for minor CRI (12); and (d) 
about one-third of CRIm + Abs were Id-related to CRIc, the predominant IdX of 
BALB/c anti-ABA Abs (10,  13).  We here refer to the last-mentioned group as 
CRL, +.  In  addition,  a  substantial  fraction  lacks  any  demonstrable  intrastrain 
cross-reactive idiotype. These relations are illustrated in Fig.  1. 
Recently, we, as well as others (14), have become interested in the Id character 
of the Ab response induced by T  cell-independent (TI) antigenic forms of the 
ABA  hapten.  In  the  present  studies,  we  used  (killed)  Brucella  abortus  (Bru) 
organisms and S.  typhimurium lipopolysaccharide (LPS) as the directly mitogenic 
carriers.  These  were  haptenated  with  ABA  and  employed  in  sub-polycional- 
activating doses, i.e., as TI-1  Ags.  The results indicate that these Ags induce a 
different Id profile than that seen in responses to typical T-dependent (TD) Ags, 
such as ABA-KLH. 
Materials and  Methods 
Mice.  Most  (~75%)  A/J  mice  were  obtained  from  the Jackson  Laboratory,  Bar 
Harbor, ME.  Male and female mice were used at 6-16 wk of age, except for adoptive 
transfer recipients, which were female "retired breeders." 
A  smaller number of mice was  obtained from the  U.C.  Berkeley breeding facility. 
Breeders from the Jackson Laboratory are introduced there at every third generation to 
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FIGURE  1.  Relationships and relative dominance levels of IdX expressed in the A/J hyper- 
immune Ab response to ABA-KLH. Based on data of Brown et al. (1 I). The proportions 
shown should be considered as averages for a large pool of mice and not typical of  all individugl 
animals. Anti-CRIm is a Rbt anti-eRI adsorbed on an HP R16.7-Sepharose 4B column. Anti- 
eRic is Rbt anti-eRl prepared against BALB/c hyperimmune anti-ABA Abs elicited by ABA- 
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maintain uniformity. 
Breeding pairs of CBA/N mice were obtained from the National Institutes of Health. 
F~ progeny of CBA/N and A/J mice were bred at U.C., San Francisco. 
Antigens  and  hnmunization.  ABA-KLH and  ABA-CGG were prepared as  described 
(15).  ABA-Brucella  was  prepared  according  to  Lucas  and  Henry  (14),  ie.,  by  direct 
diazotization.  Purified Salmonella  typhimurium  lipopolysaccharide (LPS) was  purchased 
from the List Biological Laboratories, Inc., Campbell, CA, and reacted with an equal mass 
quantity (10 rag) of the N-hydroxysuccinimide conjugate of p-hydroxyphenylpropionic 
acid (the latter derivative being prepared according to Pohlit et al. [16]) in 2 ml dimethyl 
sulfoxide at  room  temperature.  The  product was  extensively dialyzed against  borate 
buffer (pH 9.0) and then phosphate-buffered saline (pH 7.3), before conjugation with  1 
ml 1 M ABA-diazonium salt and further dialysis. 
The TD Ags were emulsified in complete Difco adjuvant H37Ra (Difco Laboratories, 
Detroit, MI) and injected i.p., ABA-LPS was injected i.p. in PBS only, while ABA-Bru (in 
PBS) was injected i.v. into a lateral tail vein. 
Antisera.  The standard Rbt anti-CRI was prepared according to Ju et al. (17).  Prepa- 
ration of anti-Id (R16.7) and anti-CRIm  (anti-CRI adsorbed on an HP R16.7-Sepharose 
4B column) has been described elsewhere (11, 13). 
Monoclonal Abs to Thy-1.2 and Lyt-2.2 were produced by the murine hybridoma cells, 
H O-13 and HO-2.2 (American Type Culture Collection, Bethesda, M D). For Ab-mediated 
cytotoxic elimination  of lymphoid  cell  subsets,  optimal  dilutions  of the  appropriate 
supernate were employed along with agarose-adsorbed guinea pig complement (C; Gibco 
Laboratories, Grand Island, NY). 
A preparation of the rat anti-CRI mAb AD8 was provided by P. Hornbeck, U.C. San 
Francisco (18). For plaque inhibition 10 #1 of a 0.5 mg/ml solution in PBS was used. 
Cultures.  Splenocytes were adjusted to either 5 ×  10e/ml (for ABA-Bru or ABA-LPS 
cultures) or 107/ml (for SRC cultures) in culture medium (RPMI-1640 +  10% fetal calf 
serum; Gibco Laboratories), plated in 0.5-ml cultures, and left for 3 d at 37°C, without 
rocking (SRC cultures were rocked), in an atmosphere of 7% 02, 10% CO2, and 83% N2. 
Ag concentrations used were: 1/200 final dilution ABA-Bru, 1 #g/ml ABA-LPS, or 15 
ul per culture of a 0.1% suspension of SRC (Colorado Serum Co., Denver, CO). Triplicate 
cultures were pooled and assayed.  Results from at least four separate experiments are 
given for each in vitro data point. 
Hemolytic Plaque Assay.  The procedure for the plaque assay (15) was modified so that 
all antisera (anti-IdX, anti-IgM, or anti-IgG) and C, were added directly to the agar. The 
conjugation of target erythrocytes with  the  ABA-HB-imidoester was  altered from the 
protocol of Isakson et al. (19) as follows: (a) the concentration of RC in the haptenating 
mixture was 1/2.5 rather than 1/5; (b) the haptenation mixture was rocked for no more 
than  13 h; and (c) horse- or goat-RC were substituted for sheep-RC. (HB refers to the p- 
hydroxybenzimidate group.) 
Serological Assays.  Anti-ABA Abs were isolated by affinity chromatography on an ABA- 
BGG-Sepharose 4B column (13).  Radiolabeling of Abs was  done in the solid phase as 
described by Herzenberg and Herzenberg (20). Briefly, 10 t~g of a pool of anti-ABA Abs 
was passed over an ABA-BGG-Sepharose 4B column, washed, iodinated with 125I by the 
chloramine-T method (21) and washed again.  Labeled Abs were eluted with 0.5  M p- 
arsanilic acid plus  1 mg/ml BSA, pH 8.0. Eluted Abs were exhaustively dialyzed. Anti- 
ABA titers were determined as given elsewhere (1). 
Adoptive Transfers.  In the adoptive transfer protocol (22) recipient mice were irradiated 
(600 tad) -~6 h before reconstitution with splenocytes; and were challenged with Ag (0.2 
ml 1.25% ABA-Bru solution i.v. or 0.2 ml 10% SRC, i.p.)  12 h after reconstitution. Mice 
were maintained on acidified water. 
ld  Calculations and Statistics.  Nonspecific plaque  numbers were subtracted  from all 
PFC numbers before calculation of percent IdX ÷ PFC by the formula given previously 
(15).  The  statistical  significance  of differences of values  in  two  distinct  groups  was CONGER  ET  AL  441 
determined  using  the  nonparametric (Wilcoxon)  rank sum  test  or Student's  t  test  for 
independent groups (23). 
Results 
Disparities Between Rbt Anti-CRI and a Monoclonal Anti-V Region Ab in Inhibition 
of ABA-Specific  PFC h~duced  by  TI or  TD  Ags.  Initial  indications  that  the  Id 
character  of the  Ab response to  ABA,  induced  by TI  Ags differed from that 
induced by TD ABA Ags came from PFC inhibition  using a monoclonai rat Ab 
(AD8 kindly supplied by P. Hornbeck, UCSF) that defines Id-AD8 (18). It reacts 
with an idiotope present on several CRIA  + HP. 
A/J mice were immunized with one or more injections of either the TI-1  Ags 
ABA-Brucella or ABA-LPS or the TD Ags ABA-KLH or ABA-CGG (the latter 
two in  adjuvant).  Percentages  of primary  or  hyperimmune  ABA-specific PFC 
inhibitable with Rbt anti-CRI or with AD8 are given in Table I. The data show 
that  CRI expression correlates  well with the expression of Id-AD8  in TD,  but 
not TI, responses. The ratio values obtained indicate that >80% of CRI  ÷ PFC 
(defined by Rbt anti-CRI)  induced  by hyperimmunization  with ABA TD Ags, 
and  >90%  of those  in  the  early  primary  response  to  ABA-KLH are  also  Id- 
AD8 +.  In contrast,  only slightly greater than  half the CRI  + PFC in the in  vivo 
TI responses were also Id-AD8 +. Incorporation of both AD8 and Rbt anti-CRI 
into the plaquing medium did not result in additive inhibition (data not shown). 
Individual inhibition ratio values are given for several mice (Table I, lines 1 and 
4).  They show that,  in contrast to the primary ABA-KLH response, where the 
correlation is very close for all animals, the individual ratio values vary widely in 
the  primary  ABA-Bru  response,  from  0.21  to  0.82.  The  mean  ratio  values 
between these primary responses (TI vs. TD) differ significantly (probability of 
TABLE  I 
Idiotype and Idiotope Expression in ABA-Spec~c TD and TI PFC Responses 
Group  Antigen*  Type 
%  PFC Inhibition by:  Inhibition ratio  ! AD8/RbtaCRI 
Re- 
sponse ~  RbtaCRI  AD8 
lgM  IgG 
IgM  IgG  IgM  IgG 
1  A-K  TD  1 °  844- 10  924-  6  794- 12  91 4-  6  0.94(0.93,0.97.0.90,  0.99(0.97,  1.01, 1.00, 
0.97)  0.98, 0.99) 
2  A-K  TD  Hyp  fl  40 4- 20  --  36 4- 18  --  0.89 
3  A-CGG  TD  Hyp  --  34 4- 14  --  2fi 4- 18  --  0.83 
4  A-Bru  TI  1 °  873=  9  --  484-18  --  0.56 (0.54, 0.41, 0.82,  -- 
0.53, 0.38, 0,71, 
0.21, 0.70, 0,54, 
0.71) 
5  A-Bru  TI  Hyp  --  60 3= 17  --  33 4- 25  --  0.53 
6  A-Bru  TI  1" in vitro  72 4-  2  --  1 4- 19  --  0.01  -- 
7  A-LPS  TI  1 °  77 3= 19  --  45 4" 20  --  0.55  -- 
8  A-LPS  TI  I °invitro  58+  6  --  63=  4  --  0.13  -- 
* A-K is ABA-KLH; A-Bru is ABA-Brucella; A-COG is ABA-Chicken gamma globulin. A-LPS and TD Ags (in adjuvant) were injected i.p. while 
A-Bru (0.2 ml of a  1.25% solution) was injected i.v. 
"~ 1 ° =  primary response assayed on day 9 or I 0  for TD Ags and either day 3 or 4 for T1 responses.//)~0, hyperimmune,  at least three injections 
total. Geometric Mean PFC per spleen or per culture (in vitro responses) were for groups 1-8:27,447 (~) 18,215 ('~); 433,653 (# +  3'); 82,454 
(# +  3"); 9799 (#); 219.690 (t~ +  Y); 633 (#); 6248 (#); 518 (ta), respectively. 
! Arithmetic mean of ratios for each individual animal. Since in a  few cases all mice were not tested with both anti-ld reagents, this value may 
differ slightly from the ratio of mean values given in the RbtaCRl  and AD8 columns. 
fl In Hyp responses  to A-K or A-Bru, lgM PFC per spleen were relatively low and so were usually not determined separately from  lgG PFC. 
Primary TI responses consisted solely of lgM PFC. Values given are arithmetic means 4- 1 SD. 442  ID1OTYPES IN  T-INDEPENDENT  RESPONSES 
equality, P  <  0.001).  The most striking disparity is seen in the primary in vitro 
responses to the TI Ags. Here Id-AD8 expression is practically nil even though 
most PFC are CRI +. 
Further Evidence that CRIA Does not Dominate the CRI + Component of ABA-Specific 
TI Ab Responses.  In the next assays, a  polyspecific rabbit antiserum directed to 
the Id of HP R 16.7 (i.e., the defining antiserum for CRIA positivity) was used to 
examine antibody responses. A/J mice hyperimmunized with ABA-Bru produced 
sufficiently high titers of anti-AAB Abs (mostly IgG) for serological analysis, Sera 
were obtained from A/J mice hyperimmunized (>3 injections) with either ABA- 
Bru (5 mice) or ABA-KLH (4 mice) and tested for total content of anti-ABA Abs 
and the proportion that was CRIA +. The data in Table II indicate, first, that the 
anti-ABA titers of the ABA-Bru  sera averaged  "~20 times lower than those of 
the ABA-KLH sera. This result is different than that seen in the plaque assay, in 
which hyperimmune responses to these two Ags were often comparable (Table 
I).  The  discrepancy  may  reflect the  fact  that  the  serum  Ab  assay  detects  Ab 
accumulation, whereas the PFC analysis provides an "instantaneous" picture only. 
Anti-ABA Abs from serum samples were affinity-purified and tested for their 
capacity to inhibit the binding of ~25I-labeled HP R16.7 to Rbt anti-CRI (Table 
II, column 3). An average of 39 ng of Abs from the ABA-KLH sera was required 
to cause  50%  inhibition,  whereas  -~7  times as  much--282  ng--was  required 
from the ABA-Bru sera. This demonstrates that, on a proportional basis, ABA- 
specific Abs induced by ABA-KLH contained seven times as much CRIA as those 
induced by ABA-Bru.  However, a  substantial  fraction of the  Abs  in  the  anti- 
ABA-Bru  sera  was  nonetheless  CRI +,  as  shown  by  the  data  in  the  last  four 
columns of Table II.  A  pool of ABA-specific Abs from the ABA-Bru sera was 
prepared by combining equal weight quantities  from each of the samples,  and 
labeled  with  125I. A  total  of 42%  of the  Ab  (which  is  60%  of the  maximum 
precipitable by anti-Fab) could be precipitated with the anti-Id (R 16.7) and anti- 
CRI,,.  (Anti-CRIm  is  a  Rbt  anti-CRI  serum  preadsorbed  on  an  HP  R16.7- 
TABLE  II 
CRIa and CRI,,, Expression in Serum Abs Induced by ABA-KLH or ABA-Bru 
Anti-ABA 
Ag*  titer* 
Anti-ABA Ab required for 
50% inhibition  0 
% Labeled anti-ABA Ab bound by 
anti:  ! 
Mouse  Fab  CRI  Id R16.7  CRI. 
#g/ml  ng 
ABA-KLH  3,675 4- 826  39 +  19  NT  72  55  NT 
(28, 49, 60, 18) 
ABA-Bru  181 4- 136  282 4- 136  70  NT  12  30 
(115,358, 450, 312, 176) 
* Sera were from mice immunized three times with ABA-KLH (i.p. in adjuvant) or four times with 
ABA-Bru (i.v.). 
* Arithmetic means 4- 1 SD, column 2 and 3. 
0  Each test utilized 10 ng of 125I-labeled HP R 16.7 and slightly less than an equivalent amount of Rbt 
anti-CRI. 
t Values given represent plateau levels of precipitation for each reagent. Excess  goat anti-Rbt Fc was 
used to precipitate complexes. NT, not tested. CONGER  ET  AL.  443 
Sepharose  4B  column.)  Interestingly,  more  than  twice as  much  material  was 
precipitable with the anti-CRIm serum as with the anti-Id R 16.7 serum (30% vs. 
12%, respectively). This result has never been seen with anti-ABA Abs induced 
by ABA-KLH.  For  comparison,  results  obtained  using  pooled anti-ABA  Abs 
from ABA-KLH sera (different from those used in the inhibition assay) are also 
presented  in  Table  II.  72%  of these  Abs were precipitable  with  Rbt anti-CRI 
and  55%  with  Rbt anti-Id  R16.7,  indicating  that  76%  of the  CRI  ÷ Abs were 
CRIA  +, while only ,~ 24% were CRIm  +. Except for the somewhat high percentage 
of CRI  ÷ Abs (30-50%  is  more typical),  this  result  is similar  to those reported 
previously by Brown et ai. (11). 
The same question was explored by plaque analysis, using anti-Id R16.7 as an 
inhibitor.  The results in Table III are similar to those obtained using AD8 as an 
inhibitor of plaques. The ratio values (anti-Id R 16.7/anti-CRI) of 0.92 and 0.96 
for ABA-CGG and  ABA-KLH,  respectively,  indicate  that  >90%  of the  CRI  ÷ 
PFC induced by these TD Ags were CRIA  +. In contrast, only ~  50-60% of CRI  + 
PFC induced in vivo by ABA-Bru or ABA-LPS, respectively, were CRIA  +. Once 
again, these lower average values reflect the presence of some individual animals 
with a  high,  and  some with a  low relative proportion  of CRIA.  Note also that 
CRIA expression was again very weak in the primary in vitro response to ABA- 
Bru.  <30%  of the  CRI  ÷  PFC  were  CRIA  ÷  and  this  figure  may  actually  be 
somewhat artifactually inflated due to some nonspecific inhibitory activity (up to 
15%) of the particular Rbt anti-Id R16.7 used. 
CRIb, Is Only Weakly Expressed  in the TI Responses.  The preceding data indicate 
that  one or more members of CRIm is at  least equi-dominant  with  CRIA in  in 
vivo responses  to  ABA  TI-1  Ags,  and  considerably  more  preponderant  in  in 
vitro responses to the same Ags. The possibility was considered that most of the 
CRIm  + PFC induced by the TI Ags were CRIc,  +. The data in Table IV indicate 
that this is probably not the case.  PFC inhibition by a  Rbt anti-CRIc, antiserum 
prepared against the CRI¢,  + HP 36-60 (anti-Id 36-60 kindly provided by Dr. A. 
Marshak-Rothstein,  Massachusetts Institute of Technology) was practically neg- 
ligible for the anti-ABA responses induced by the TI Ags. In contrast, this same 
antiserum completely inhibited PFC produced by the CRI¢  + (i.e., BALB/c origin) 
hybridoma cells, CH.BALB (kindly provided by Dr. C. Henry and M. Slomich, 
TABLE  III 
Comparative Expression of CRl and Id R16.7 in Primary IgM anti-ABA PFC Responses 
% PFC inhibition by:  Inhibition ratio 
Group  Ag*  RbtaCRI  RbtaId R16.7  aIdR16.7/ 
aCRI* 
1  A-K  86 _  6  83 _+ 7  0.96 
2  A-CGG  64 ___  15  60 +  18  0.92 
3  A-Bru  91  +  7  45 ___ 22  0.49 
4  A-Bru (in vitro)  57 __. 13  14 +  11  0.29 
5  A-LPS  92 +  7  56 _  27  0.61 
* See Footnotes to Table I. Day-6 response for A-K, day 9 for A-CGG, and day 3 or 4 for A-Bru and 
A-LPS. Geometric mean PFC per spleen or per culture (# +  ?  for A-CGG, all others # only) were 
for groups 1 thru 5:  16,482;  18,583;  11,731; 578; 6,311, respectively. 
* Ratio values for TI responses differ significantly from those for TD responses, P<.01. 444  1DIOTYPES  IN  T-INDEPENDENT  RESPONSES 
TABLE  IV 
CRL' (Id 36-6°) Expression in Primary PFC Responses to ABA-TI Ags 
Group  Ag*  Response 
% PFC inhibition by: 
RbtaCRl  Rbtald 36-6° 
1  --  CH.BALB cells*  100  100 
2  A-Bru  In vivoJ  87 ±  12  14 4- 15 
3  A-Bru  In vitro  72 ±  3  3 ±  11 
4  A-LPS  In vivo  91  +  9  7 ±  9 
5  A-LPS  In vitro  54 ±  5  12 -+ 8 
* See Footnotes to Table I. 
* CH.BALB  cells  are  hybridomas  made  by  fusing ABA  hyperimmune 
spleen cells from a BALB/c mouse with cells of the NS-1 line. They 
secrete IgM anti-ABA Ab which is CRIc  ÷ by PFC inhibition (communi- 
cated by Dr. C. Henry). 
0  Geometric mean PFC response numbers (all ~t) per spleen or per culture 
for groups 2-5 were: 12,708; 330; 6,063; 321, respectively. 
UC Berkeley). 
Weak  Expression  of CRIA  in  TI Responses Is Probably Not Due  to  Ts  Cell Activ- 
i(v.  One possibility to explain the weak expression of CRIA in the TI responses, 
compared  with  TD  responses,  would be that  CRIA-specific Ts cells are  more 
active in the former than  in the latter.  On this basis, if T  cells are eliminated it 
would be expected that the CRIA/CRI ratio would increase in responses to ABA- 
Bru. To test this,  normal or anti-Thy-l.2  plus C-treated spleen cells (2.5 ×  106 
per  0.5-ml  culture)  from  unprimed  or  SRC-primed  (day  -3)  A/J  mice  were 
cultured in the presence of ABA-Bru or SRC, respectively. Cultures were assayed 
on day 3. The data (Table V) show that anti-Thy-l.2 treatment did not decrease 
the number of PFC induced by ABA-Bru, but it did reduce the (secondary) anti- 
SRC  PFC  by  85%.  (The  anti-SRC  response  has  been  reported  by others  to 
contain  a  small  TI  component  [24].)  However, the  CRIA/CRI  ratio  was  not 
increased  in  the  cultures  containing  cells treated  with  anti-Thy-l.2  plus  C;  if 
anything,  it  decreased  somewhat  although  the  difference  is  not  statistically 
significant. Similar experiments were done using adoptive transfer methodology 
(lower  half  of Table  V). Irradiated  (600  rad)  recipients  received  4-5  ×  107 
normal or anti-Thy-l.2 plus C-treated splenocytes, followed by either ABA-Bru 
or SRC (control). The results were similar--the CRIA/CRI ratio did not increase. 
Furthermore,  in a  few experiments anti-Thy-l.2  treatment  was replaced by an 
elimination  step  using  anti-Lyt-2.2  plus  C.  Again,  comparable  results  were 
obtained (data not shown). 
b~uence  of the  xid  Defect on  CRIa  Expression.  One  of the  models  that  we 
considered for explaining the preceding data (see Discussion) was that CRIA and 
CRIm might be asymmetrically expressed by functionally distinct B cell subpop- 
ulations.  It is known (25) that mice expressing the CBA/N xid gene(s)--CBA/ 
N mice or male Fl progeny of CBA/N females and normal malesmlack a major 
B cell subpopulation (Lyb-5+). For this reason, we bred F~ progeny of CBA/N 
female and A/J male (--NAFI), as well as offspring of A/J female and CBA/N 
male (=ANF1), and examined their anti-ABA  PFC responses induced by ABA- 
Bru. The results in Table VI demonstrate that the normal Fl mice express CRIA CONGER  ET  AL. 
TABLE  V 
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Response  Ag*  Treatment  PFC/cul-ture  Reduc-tion  CRI+  CRIA÷/CRI  +* 
In vitro 
In vivo adoptive transfer  A-Bru 
A-Bru 
%  % 
A-Bru  C  528  55  0.36 
-4  A-Bru  Anti-Thy-  1.2  550  64  0.18 
+C 
SRC  C  12,333  85 
SRC  Anti-Thy-1.2  1,845 
+C 
C  2'922u  18  83  0.54 
Anti-Thy-l.2  2,392  g  71  0.53 
+C 
SRC  C  25'0841  87 
SRC  Anti-Thy-1.2  3,294  ° 
+C 
* See  footnotes to Table  I.  SRC  is sheep erythrocytes.  Culture conditions and adoptive transfer 
details are given in the text. 
* % CRIA  + is an average figure based on inhibition obtained with both AD8 and Rbt anti-Id R16.7. 
0 Geometric mean specific PFC per recipient spleen. Each figure based on results from at least seven 
recipients. 
TABLE  VI 
Relative Magnitude and CRIA Representation in Anti-ABA-Bru 
Responses of Fl Progeny of CBA/N and A/J Mice 
Mice*  PFC/Spleen*  %CRIA  +§ 
NAFI ~  12,210  36 
NAFI d (xid)  3,395  16 
ANFl ~  3,429  39 
ANFI d  7,555  38 
* Mice received one i.v. injection of 0.2  ml of 1.25%  ABA-Bru in PBS 
and were plaqued on day 4 (peak of the response for all animals). Results 
for 7 or 8 mice of each of the indicated types are given. 
* Geometric mean IgM PFC/spleen. 
0 Arithmetic mean of %Id-AD8  + and % ld-R16.7 ÷ PFC. 
at slightly lower levels than do A/J mice; however, responses by the NAF1 male 
xid animals were particularly depleted of CRIA. In the response to ABA-Bru by 
the three  normal  types of F~  mice,  CRIff PFC varied from  2  to 68% of anti- 
ABA PFC, with means of 35-40% in each case. In contrast, NAFx male responses 
ranged  from  0-29%  CRIA  + with  a  mean  of  16%,  which  is significantly  lower 
than the means of all three of the normal groups (P <  0.05). 
Discussion 
The present data show that the Id profiles of A/J ABA-specific Ab responses 
induced by TD and TI  forms of ABA are distinct.  Two different CRI popula- 
tions,  CRIA and  CRIm,  show differential  relative representation  in the TI  and 
TD responses. CRIA overwhelmingly dominates (>90%) the CRI  ÷ component of 
the primary in vivo PFC response induced by the TD Ags ABA-KLH and ABA- 446  IDIOTYPES IN  T-INDEPENDENT RESPONSES 
CGG, at least around the peak of the response (day 9 or 10). Secondary responses 
to TD Ags also show predominance of CRIA among the CRI  + PFC, i.e., >80% 
of CRI  + PFC are  CRIA  +.  This  result  is in accord with  the serologic studies of 
Brown et al.  (11).  In contrast,  a  significantly lower percentage of CRI  + PFC-- 
slightly more on average than  50%--were CRIA  + in primary and hyperimmune 
in vivo responses to ABA-Brucella or ABA-LPS. When individual animals were 
examined  for their  CRIA/CRI  ratios  among  primary  PFC activated  by ABA- 
KLH or ABA-Bru, values of >0.9  were seen for all animals  in  the case of the 
former Ag, whereas, in responses to the TI-1  Ag, ratio values of well below 0.5 
were seen in some mice, indicating  CRIm predominance.  Serologic comparison 
of the in vivo hyperimmune Abs induced by ABA-Bru and ABA-KLH demon- 
strated that the CRIA/CRI ratios in the two responses were at least as discrepant, 
if not more so, than the PFC analysis indicated. However, the weakest expression 
of CRIA was noted to occur in primary in vitro PFC responses to ABA-Bru and 
ABA-LPS. Thus, the magnitude of the CRIA/CRI ratio shows the order:  1 ° TD 
in vivo >  2 ° TD in vivo >  1 °,  2 ° TI in vivo >  1 ° TI in vitro. The CRIm/CRI 
ratio  follows (by definition)  exactly the  reverse order.  The  ABA hapten,  pre- 
sented in TI-1 form, appears to activate a more heterogeneous idiotypic response 
than  it does when  presented  in  TD form.  The  major fraction  of the  PFC  (or 
Abs) induced by the TI-1  Ags are CRI  ÷, but not CRIA  +. 
One or more members of CRIm is at least equi-dominant with CRIA in ABA- 
specific TI-l-type  Ab  responses  in  A/J  mice,  in  contrast  to  responses  to  the 
potent TD Ags, ABA-KLH or ABA-CGG, where CRIA predominates.  But what 
member(s)  of this  heterogeneous  group  (26)  is  expressed?  (Here  it  might  be 
noted that two nonequivalent definitions for CRIm were previously offered: one 
based on the presence of direct binding of anti-ABA Abs to Rbt anti-CRI, along 
with very weak inhibition  of the standard CRI-anti-CRI reaction (12), while the 
second definition (26) required direct binding by Rbt anti-CRI with concurrent 
lack of same by Rbt anti-Id R 16.7. The criterion used herein is the second one; 
PFC inhibition by anti-Id is clearly a direct binding assay.) Several types of CRIm 
components have been defined. One of these is CRIc, (10, 11). Data given in this 
report,  however, indicate that  CRIc, is only a  very minor component in the TI 
responses, including the in vitro ones. Another class of CRIm  + molecules have L 
chains (but not H  chains) corresponding serologically to those present in CRIA  + 
molecules (27). Another possibility would be that most of the CRIm  + Abs are Id- 
related to the 96B8 family (9).  Finally, many of the CRIm  ÷ Abs might be CRIA- 
related but represent extensively altered somatic variants that have lost the most 
immunodominant  CRIA-IdX  determinants.  Further  serological  and  structural 
analyses of the CRIm  + Abs elicited by the TI  Ags will  be required to pinpoint 
the exact nature of these. 
The  most extreme  example  of Id profile discrepancy  from  the  TD pattern 
involves the in vitro primary TI responses. The expression of CRIA was consid- 
erably weaker in these responses than in in vivo responses to the same Ags. Our 
data concurs with those presented in a communication of Robertson et al. (28). 
These  workers  reported  that  none  of their  ABA-specific  B  cell  hybridomas, 
generated using A/J lymphocytes polyclonally stimulated in vitro with LPS and 
dextran  sulfate,  secreted CRI  + Abs.  Presumably,  CRI positivity was examined CONGER  ET  AL.  447 
using the competition RIA which detects only CRIA  + Abs. The unusual Id profile 
was elicited irrespective of hapten-receptor interaction, since the mitogens used 
were not ABA-substituted. Thus, the lack of activation of CRIA  + clones cannot 
be  attributed  to  the  preferential  stimulation  of B  cells  bearing  high  affinity 
receptors for ABA.  It seems that  virgin,  ABA-specific, CRIA  + B  cells may be 
refractory to  in  vitro  activation.  This  seems to  us  to  be  strongly  suggestive 
evidence that CRIA determinants may be selectively expressed by B cells belong- 
ing to a particular subset. It is also likely that this property of CRIA  ÷ precursors 
accounts for our total inability to induce anti-ABA responses in vitro to TD ABA 
Ags using unprimed A/J B cells, even in the presence of carrier-primed T  cells. 
The likeliest theories for explaining the present data would invoke the differ- 
ential activation, in different types of responses, of either B cell subsets or T  cell 
subsets.  In the latter case, one could propose, in accordance with the network 
hypothesis (29)'  that  particular  Id-specific Th  or  Ts  cells play  quantitatively 
different roles in TI  vs.  TD responses. The data obtained in the experiments 
involving anti-Thy-1- (or anti-Lyt-2-) treated A/J splenocytes would, however, 
tend to rule out enhanced activity of CRIA-specific Ts cells as being responsible 
for  the  low  CRIA  expression  observed  in  the  TI  responses.  This  leaves  the 
possibility that CRIA-specific Th cells are more active in in vivo responses to TD 
ABA Ags than  to  TI  ABA Ags.  While it  is  logically difficult to see why this 
would be the case, this theory cannot be formally ruled out. 
In fact, the hypothesis that seems most consistent with the data is one based 
on the differential expression of IdX dominance by functionally distinct B cell 
subpopulations,  with  the  selective activation  of these  subsets  under  different 
conditions. The differential expression of Ig V  region elements by different B 
cell subsets is not a novel idea: Slack et ai. (30) originally suggested this possibility 
and the data of Ward et al. (31) and Primi et al. (32) supports this hypothesis. 
Furthermore, Wicker et al. (33) have recently presented evidence that BALB/c 
PC-specific B cell precursors which belong to the Lyb-5  + subset are largely T15 
IdX +, while those in the Lyb-5- subset are almost entirely T 15 IdX-. A similar 
situation may exist among A/J ABA-specific B cell precursors, and we propose 
the following model. ABA-specific B cell precursors belonging to subset  1 are 
predominantly (75-100%) CRIA  ÷, while those in subset 2 are at least 50% CRIm  + 
with a lower, and variable, proportion being CRIA  ÷ (0-30%).  In vitro challenge 
of A/J splenocytes with TI-1 ABA Ags results in the almost exclusive activation 
of B cells in subset 2, possibly due to a  higher density of cell surface receptors 
for the polyclonal activating structures on these Ags. In contrast, in vivo challenge 
of A/J  mice with  ABA conjugates of TD  carriers,  such as  KLH,  apparently 
results in  the almost exclusive activation of ABA-specific B cells belonging to 
subset 1. In vivo challenge with TI-l-type ABA Ags results in the stimulation of 
both subpopulations, although one or the other subset may tend to predominate 
in different individuals; this would explain the IdX profile variation seen in mice 
responding to ABA-Bru or ABA-LPS. 
The preceding functional properties attributed  to  subsets  1  and  2  are  not 
purely  speculative  but,  rather,  are  based  on  reported  properties  of B  cells 
belonging, respectively, to the Lyb-5  ÷ and Lyb-5- subsets (34, 35). Furthermore, 
(CBA/N  ×  BALB/c)FI (NBF1) male mice gave almost no primary anti-PC Ab 448  ID1OTYPES  IN  T-INDEPENDENT  RESPONSES 
response  to  PC-KLH  in  CFA  (average  1/10  the  female  NBF~  response) (36). 
This result would suggest that the primary response to this Ag in normal mice is 
almost entirely attributable to the Lyb-5  + B cell subset, and, as would be expected, 
is strongly T15-IdX dominant in BALB/c mice (37). 
At first, Sigal's recent evidence (38) that only 2.6% of unprimed ABA-specific 
B  cells from  A/J  mice  are  CRIA  + would  seem  to  contradict  our  model.  It  is 
possible,  however,  that  there  was  some  bias  in  the  splenic  focus assay  which 
resulted  in  under-representation  of CRIA  +  precursors.  In  particular,  B  cells 
belonging to our hypothetical subset 2 may have been preferentially stimulated. 
Finally, we would point out that the two types of theories--the IdX partitioning 
among different B cell subsets vs. differential Id-specific regulation by T  cells-- 
are not totally exclusive. Thus, Lyb-5- B cells may be refractory to helper factors 
produced by IdX-specific Th  cells.  Moreover,  Lyb-5  ÷ B cells may derive from 
an  Lyb-5- pool (39).  If that  is the  case,  then  CRIA-specific Th  cells might  be 
envisioned  as  playing  a  key role  in  promoting  the  selective differentiation  of 
immature  CRIA  + ABA-specific precursors  to  the  Lyb-5  + subset,  which  could 
result in a  skewed IdX  representation  between the two B cell subsets. To test 
these ideas it would be highly informative if the anti-ABA responses of A/J nu/ 
nu mice (or B cells therefrom) could be examined. 
Summary 
Two different cross-reactive idiotype (CRI) groups are distinguishable  in the 
Ab response of A/J mice to the p-azobenzenearsonate (ABA) hapten:  CRIA and 
CRIm. These two groups showed distinct patterns of relative dominance in the 
ensuing response depending on whether the inducing Ag was a T  cell-dependent 
(TD) form of ABA, such as ABA-KLH or ABA-CGG, or a T-independent  type 
1 (TI-1) form,  such as ABA-Brucella abortus or ABA-lipopolysaccharide (LPS), 
and on whether the response was elicited in vivo or in vitro. The CRI  ÷ component 
of primary  in  vivo plaque-forming  cell  (PFC) responses  to  TD  ABA  Ags was 
largely (>90%) CRIA  ÷ as was, to a slightly lesser extent (>75%) the CRI  + portion 
of secondary or hyperimmune serum Ab or PFC responses to the same Ags. In 
contrast, in vivo primary and hyperimmune PFC responses to ABA-Bru or ABA- 
LPS showed a significantly lower CRIA/CRI ratio, averaging 0.5-0.6, with some 
individual  mice giving figures as low as 0.2,  indicating predominance  of CRIm 
over CRIA. Serological analysis of hyperimmune anti-ABA Abs from a group of 
5 A/J mice immunized with ABA-Bru gave a figure of <0.5 for the CRIA/CRI 
ratio.  The most striking  disparity from the TD pattern was seen in primary in 
vitro PFC responses to the TI ABA Ags; here ratios of<0.2 were generally seen. 
Since T  cell removal  did not alter  the  Id pattern  in  the  TI  responses,  CRIA- 
specific Ts cells do not account for the weak expression of CRI^ in such responses. 
We  propose  a  model  that  explains  these  results  on  the  basis  of differential 
expression of IdX dominance by two distinct B cell subpopulations--equatable 
to the Lyb-5  ÷ and Lyb-5- B cell subsets--along with differential relative activa- 
tion of these subsets in different types of responses.  Examination  of anti-ABA 
PFC responses of F~ progeny of CBA/N and A/J mice to ABA-Bru lends support 
to this hypothesis since CRIA expression was significantly lower in mice with the CONGER  ET  AL.  449 
xid defect. 
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